Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin. 2022

Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
College of Pharmaceutical Science & Collaborative Innovation Center for Yangtze River Delta Region Green Pharmaceuticals, Key Laboratory of Marine Fishery Resources Exploitment & Utilization of Zhejiang Province, Zhejiang University of Technology, 310014 Hangzhou, People's Republic of China.

Heparin products are widely used clinical anticoagulants essential in the practice of modern medicine. Low-molecular-weight heparins (LMWHs) are currently prepared by the controlled chemical or enzymatic depolymerization of unfractionated heparins (UFHs) that are extracted from animal tissues. In many clinical applications, LMWHs have displaced UFHs and currently comprise over 60% of the heparin market. In the past, our laboratory has made extensive efforts to prepare bioengineered UFHs relying on a chemoenzymatic process to address concerns about animal-sourced UFHs. The current study describes the use of a novel chemoenzymatic process to prepare a chemobiosynthetic LMWH from a low-molecular-weight heparosan. The resulting chemobiocatalytic LMWH matches most of the United States pharmacopeial specifications for enoxaparin, a LMWH prepared through the base-catalyzed depolymerization of animal-derived UFH.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D017984 Enoxaparin Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) Clexane,EMT-966,EMT-967,Enoxaparine,Lovenox,PK-10,169,PK-10169,EMT 966,EMT 967,EMT966,EMT967,PK 10,169,PK 10169,PK10,169,PK10169

Related Publications

Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
January 2011, Bioorganicheskaia khimiia,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
July 2000, American heart journal,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
January 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
May 1985, La Revue du praticien,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
January 1988, La Revue de medecine interne,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
May 1994, The Medical clinics of North America,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
April 1998, RN,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
September 1997, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
December 1997, Recenti progressi in medicina,
Yanlei Yu, and Li Fu, and Peng He, and Ke Xia, and Sony Varghese, and Hong Wang, and Fuming Zhang, and Jonathan Dordick, and Robert J Linhardt
July 1993, Thrombosis and haemostasis,
Copied contents to your clipboard!